Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Resolution Crystallization. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN103694230A reveals amino acid eutectic purification for Canagliflozin. Achieve <0.5% alpha-impurity with scalable, cost-effective pharmaceutical intermediate solutions.
Patent CN102391145B details a water-based recrystallization method for ubenimex intermediates, offering high purity and cost-effective manufacturing solutions.
Novel chiral resolution patent CN103086877B enables high-purity pharmaceutical intermediates with reduced costs and scalable production for global supply chains.
Patent CN104030996B details a novel Valsartan refining method ensuring high optical purity and yield. Discover cost-effective supply chain solutions for chiral API production.
Patent CN1027503C details a superior crystalline salt form of 4-(di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenzo[cd]indole, offering enhanced purity and scalable manufacturing for CNS drug development.
Patent CN101531647B details a safe resolution method for Ramelteon intermediates. Discover cost-effective supply chain solutions and high-purity manufacturing capabilities.
Novel method for beta-lactamase inhibitor intermediate chiral impurities. High purity ee>99.5%. Cost-effective supply chain solutions for pharma QC.
Advanced chiral resolution for pyridoindole derivatives offering high optical purity. Discover cost-effective manufacturing and reliable supply chain solutions for pharmaceutical intermediates.
Patent CN112724129A details a novel chiral purification method for moxifloxacin intermediates, offering superior ee values and scalable industrial production for reliable supply chains.
Patent CN101910101A reveals a novel aliphatic hydrocarbon recrystallization method boosting optical purity to >99% ee for pharmaceutical intermediates efficiently.
Patent CN1442407A details a cost-effective resolution method for fexofenadine intermediates, ensuring high purity and scalable supply chain reliability for global pharmaceutical partners.
Patent CN115010686A details a novel resolution for 2-oxabicyclo-[3.3.0]oct-6-en-3-one, offering high purity and scalable manufacturing for global pharmaceutical supply chains.
Patent CN1161689A enables high-purity levobupivacaine production with reduced resolving agent usage and improved supply chain reliability for pharmaceutical manufacturers globally.
Advanced resolution method achieving >99% ee for S-3-cyclohexenecarboxylic acid, optimizing Edoxaban intermediate supply chains with cost-effective recycling.
Advanced optical resolution process for 2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidine-1-propanone. Enhances purity and supply chain reliability for pharmaceutical manufacturing.
Patent CN103755582A details a novel direct resolution of DL-serine using cyclic phosphates. This report analyzes cost reduction in API manufacturing and supply chain reliability.
Patent CN104151229B details a high-yield resolution process for Levamlodipine intermediates using DMSO-d6, offering significant supply chain stability and purity advantages for pharmaceutical manufacturing.
Patent CN113214267B reveals a novel one-step crystallization method for eszopiclone, offering high purity and significant cost reduction in pharmaceutical intermediates manufacturing.
Patent CN111004179B details a high-purity resolution method for 5'-methoxylaudanosine, offering superior yield and optical purity for neuromuscular blocker synthesis.
Patent CN114573411B reveals a safer synthesis route for Palonosetron intermediates, eliminating n-hexane and improving purity for reliable pharmaceutical intermediates supplier partnerships.